
29 Apr 2024
Oxford BioMedica (OXB LN, 475p, Buy) (Results Review) - FY23: c.+10% on adjusted EBIT, but impairments steal the beat
This content is only available within our institutional offering.

Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Oxford BioMedica (OXB LN, 475p, Buy) (Results Review) - FY23: c.+10% on adjusted EBIT, but impairments steal the beat
Oxford BioMedica plc (OXB:LON) | 614 116.7 3.2% | Mkt Cap: 738.1m
- Published:
29 Apr 2024 -
Author:
Miles Dixon | Leolie Telford-Cooke -
Pages:
8 -